Kj. Scheidegger et al., Estradiol decreases IGF-1 and IGF-1 receptor expression in rat aortic smooth muscle cells - Mechanisms for its atheroprotective effects, J BIOL CHEM, 275(49), 2000, pp. 38921-38928
Insulin-like growth factor (IGF-1) is a potent mitogen for vascular smooth
muscle cells, Both IGF-1 and its receptor have been shown to be highly expr
essed in atherosclerotic lesions. Here we investigated whether part of the
vasculoprotective properties of E-2 may be mediated by its negative regulat
ion of the IGF-1 system. HeLa cells, which do not contain endogenous estrog
en receptors (ER), were transiently 'transfected with IGF-1R promoter const
ructs with or without a plasmid encoding human ER alpha or ER beta and trea
ted with 100 nM 17 beta -estradiol (E-2) for 24 h. E-2 treatment decreased
basal luciferase activity by 51%, and this effect was dependent on co-expre
ssion of ER alpha, whereas no repression was observed with ER beta. A mutat
ion within the DNA binding domain of the ER alpha abolished the repressor f
unction of the ER receptor. Similarly, E-2 decreased IGF-1R transcription b
y 21% in rat aortic smooth muscle cells (RASMC), which express endogenous E
R, This effect was specific for E-2, because it was inhibited by an antiest
rogen and because progesterone did not have any effect on IGF-1R expression
in HeLa or RASMC transfected with progesterone receptor. Accordingly, E-2
decreased IGF-1R and IGF-1 mRNA in RASMC by 47% and 33%, Western blot analy
sis and radioligand binding studies showed that E-2 also dose-dependently d
ecreased IGF-1R protein expression in RASMC by 40% and 30%, respectively, a
nd that IGF-1 protein was reduced by 43%. Repression of IGF-1R promoter act
ivity by a combination of ER alpha and E-2 did not appear to be mediated vi
a direct binding of ER to the IGP-1R promoter but rather by inhibition of S
P1 binding to the IGF-1R promoter. Thus, E-2 down-regulates IGF-1R and IGF-
1 expression in vascular smooth muscle cells, This may have important impli
cations for the understanding of the beneficial effects of estrogen in the
cardiovascular system.